HireQuest (HQI) Q1 2026 Earnings Transcript

HireQuest reported Q1 2026 revenue of $6.5 million, down 12.7% year over year due to the MRI Network divestiture, but adjusted EBITDA held nearly flat at $2.7 million and diluted EPS rose to $0.11 from $0.10. Excluding the divestiture, system-wide sales were roughly flat at $102.6 million, while management said commercial demand improved broadly and early Q2 trends were more favorable. The company also maintained a debt-free balance sheet with $40.3 million of credit availability and reiterated its quarterly $0.06 dividend, alongside a renewed $105 million all-cash offer for TrueBlue’s PeopleReady segment.

Analysis

HQI is behaving less like a cyclical staffing beta and more like a cash-generative roll-up with an operating leverage floor. The key signal is that the core franchise model is absorbing a weak tape without destroying margins, which means any incremental improvement in demand should fall through disproportionately to EPS and dividend capacity rather than just linearly lifting revenue. That makes the stock more interesting as a second-derivative play on labor recovery than as a pure top-line recovery story.

The bigger setup is competitive share capture. Management’s comments imply the company is winning in commercial and industrial niches where staffing demand is tied to shorter-cycle project work, which tends to recover earlier than broad-based temp labor. If that holds, HQI can keep taking share while weaker peers remain distracted by balance-sheet repair, and that creates a multi-quarter compounding effect that the market likely still underestimates.

The TrueBlue bid is the real optionality, but it cuts both ways. If HQI gets even a partial deal done, the market will start capitalizing a faster growth, larger-scale platform with higher service density; if it stalls again, investors may punish management for spending time on M&A theater instead of execution. In my view the asymmetry is still favorable because the offer itself signals discipline and gives management a credible external catalyst over the next 1-2 quarters.

The contrarian risk is that the recent improvement is being overstated as structural when some of it may simply be normalization after a weather/holiday-distorted start. If labor demand rolls over again, the downside is not a profitability collapse but a multiple compression on the belief that the business has inflected. The market will care most over the next 4-8 weeks: sustained weekly improvement would likely rerate the name, while a fade would turn this back into a low-growth dividend stock.

Key Decisions for Investors

• Long HQI as a 3-6 month tactical position: upside comes from operating leverage plus a possible re-rating if weekly demand remains positive; risk is a return to flat comps, which likely caps multiple expansion.
• Buy HQI Jan-2027 call spreads to express the M&A optionality with limited downside: the TrueBlue bid creates a binary catalyst, and a spread reduces theta bleed if the deal drags on.
• Pair trade long HQI / short a weaker staffing peer basket over 1-2 quarters: HQI’s franchise model and balance sheet should outperform if the labor recovery remains uneven and share gains continue.
• If already long, sell out-of-the-money covered calls against HQI into any TrueBlue-driven pop: the stock’s dividend plus deal speculation may compress near-term upside unless a transaction actually materializes.
• Monitor TBI for event-risk positioning: if HQI forces a credible process, TBI becomes a catalyst name; if not, the bid should be treated as optionality with low conviction rather than a base-case M&A outcome.